HES Coils
GREAT: Randomized controlled multicentre study comparing HydroSoft™ / HydroFrame™ and bare platinum coils for endovascular aneurysm treatment
"Our results suggest that endovascular coil embolization with second-generation hydrogel coils may reduce the rate of unfavorable outcome events in patients with small- and medium-sized intracranial aneurysms."
- Patients
484
- Countries
France & Germany
- Clinical Centers
22
- Design
RCT (243 HES vs 241 BPC)
- Scope
Patients 18-75 y.o. with an untreated aneurysm, ruptured or unruptured, with a dimater between 4 and 12mm, WFNS <4.
- Purpose
To compare clinical and angiographic outcomes of second-generation Hydrocoils (HydroSoft™ and Hydroframe™) versus bare platinum coils.
Endpoints
Composite outcome: Major aneurysm recurrence on follow-up angiography + any aneurysm retreatment + morbidity that prevented patients from having angiographic controls (mRS between 3 and 5) + any death within 18 months after treatment.
Efficacy results
At 18 months:
Unfavorable composite primary outcome (recurrence, retreatment, morbidity, mortality): 19.9% (HES) vs 28.7% (BPC)
Complete occlusion: 69% (HES) vs 53% (BPC)
Major recurrence: 12% (HES) vs 18% (BPC)
Retreatment rate: 3% (HES) vs 6% (BPC)
Safety results
Procedural complications: 12.7% (HES) vs 12.4% (BPC)
14-day mortality rate: 2.0% (HES) vs 2.1% (BPC)
At 18 months:
mRS 3-5: 3% (HES) vs 1% (BPC)
mRS 6: 3% (HES) vs 4% (BPC)
Rupt. An (within 30 days):
mRS 3-5: 5% (HES) vs 2% (BPC)
mRS 6: 5% (HES) vs 7% (BPC)
Unrupt. An:
mRS 3-5: 1% (HES) vs 1% (BPC)
mRS 6: 1% (HES) vs 2% (BPC)
Study publications
SPONSOR: Freiburg Hospital Germany
Please refer to IFU for the full list of risks, contraindications, warnings, and precautions.
Explore more studies
Request more information
By submitting, you agree to our privacy policy.